Adrenomed

Executive Summary

Adrenomed AG is a German private clinical-stage biopharmaceutical company developing precision therapies for critically ill patients with septic shock. Its lead candidate, enibarcimab (formerly Adrecizumab), is a humanized monoclonal antibody targeting the vasoactive peptide adrenomedullin. The company employs a biomarker-driven approach using bio-ADM and DPP3 levels to identify patients most likely to benefit from treatment, aiming to restore vascular integrity and reduce mortality. Adrenomed is currently conducting a Phase 3 trial (ENVASYS) evaluating enibarcimab in septic shock patients with elevated bio-ADM. The trial is fully enrolled, with top-line data expected in the first half of 2026. The company has received orphan drug designation from the FDA and EMA, and has secured funding from investors including BioMedPartners. A successful readout could position enibarcimab as a first-in-class therapy for a major unmet need in critical care, potentially transforming outcomes in septic shock. However, as a private company, Adrenomed lacks public market catalysts and may seek a partnership or IPO upon positive data.

Upcoming Catalysts (preview)

• H1 2026Phase 3 ENVASYS top-line data readout60% success
• H2 2026Regulatory submission (BLA/MAA) for enibarcimab50% success
• H2 2026Partnership or licensing deal for commercial rights40% success